Laboratory Procedure
Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss
orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables
UPDATE: With looming Trump tariffs, pharma companies demand changes to stay in EU
EU, Pharma, Industry, Transplant Registry Unified Management Program, Policy, Investments, United States, drug price
U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs
U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact
Future-proofing gene therapy assays: Validation strategies for long-term success
Long-term, Validation, Biological Assay, Develop
Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France
Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies
LinusBio Introduces ClearStrand-ASD: Revolutionary Autism Diagnostic Aid Using Hair Analysis
LinusBio, ClearStrand-ASD, autism diagnostic, hair analysis, biomarker test, early detection, negative predictive value, exposome medicine
23andMe Restructures, Cuts 40% of Workforce and Ends Therapeutics Division Amid Financial Struggles
23andMe, layoffs, therapeutics division, financial struggles, genetic testing, data security
TCT 2024: Johnson & Johnson’s Abiomed Successfully Completes Pivotal Study for Innovative Shrinkable Heart Pump, Impella ECP
TCT 2024, Johnson & Johnson, Abiomed, Impella ECP, Shrinkable Heart Pump, High-Risk PCI, Cardiogenic Shock, FDA Approval
GC Therapeutics Secures $75 Million Funding for Revolutionary Stem Cell Technology
GC Therapeutics, George Church, stem cell startup, biotech funding, transcription factor screening
Coherus Biosciences Addresses Temporary UDENYCA Supply Interruption
UDENYCA, Coherus Biosciences, supply interruption, biosimilar, pegfilgrastim, Neulasta, cancer treatment, white blood cell count, pharmaceutical supply chain.